Patents by Inventor Wanping MAI

Wanping MAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HDAC inhibitor solid state forms
    Patent number: 12012396
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: June 18, 2024
    Assignee: Viracta Subsidiary, Inc.
    Inventors: Xiaohu Deng, Wanping Mai, Robert C. McRae, Biljana Nadjsombati
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20240166628
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: August 2, 2023
    Publication date: May 23, 2024
    Inventors: Xiaohu DENG, Wanping MAI, Robert C. MCRAE, Biljana NADJSOMBATI
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20230382888
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{(6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: October 28, 2021
    Publication date: November 30, 2023
    Inventors: Xiaohu DENG, Wanping MAI, Robert C. MCRAE, Biljana NADJSOMBATI
  • HDAC inhibitor solid state forms
    Patent number: 11760748
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: September 19, 2023
    Assignee: VIRACTA SUBSIDIARY, INC.
    Inventors: Xiaohu Deng, Wanping Mai, Robert Mcrae, Biljana Nadjsombati
  • HDAC INHIBITOR SOLID STATE FORMS
    Publication number: 20230159499
    Abstract: The present disclosure relates to the crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0 ]hex-3-yl}pyrimidine-5-carboxamide and methods of making the same. The crystalline mesylate Form 1 salt of N-hydroxy 2-{6-[(6-fluoro-quinolin-2-ylmethyl)-amino]-3-aza-bicyclo[3.1.0]hex-3-yl}pyrimidine-5-carboxamide is useful in preparation of pharmaceutical compositions and dosage forms for the treatment of cancer, immune disorders and inflammation.
    Type: Application
    Filed: December 13, 2022
    Publication date: May 25, 2023
    Inventors: Xiaohu DENG, Wanping MAI, Robert C. MCRAE
  • Synthesis of tipifarnib
    Patent number: 11542244
    Abstract: Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: January 3, 2023
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Pingda Ren, Xiaohu Deng, Wanping Mai
  • SYNTHESIS OF TIPIFARNIB
    Publication number: 20210246114
    Abstract: Provided herein are methods of preparing a desired enantiomer 6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, otherwise known as tipifarnib.
    Type: Application
    Filed: May 17, 2019
    Publication date: August 12, 2021
    Applicant: KURA ONCOLOGY, INC.
    Inventors: Pingda REN, Xiaohu DENG, Wanping MAI